[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657541":3},{"organization":4,"outcomesModule":7,"designInfo":27,"detailedDescription":35,"studyPopulation":26,"armGroups":36,"interventions":49,"overallOfficials":26,"centralContacts":57,"locations":63,"responsibleParty":79,"collaborators":26,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":85,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":26,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":108,"whyStopped":26,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"Zhongshan Ophthalmic Center, Sun Yat-sen University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":26},[9],{"measure":10,"description":11,"timeFrame":12},"Score of the Yale Comprehensive Tics Severity Scale","Three evaluation researchers who had undergone unified training and were unaware of the group assignments independently conducted blinded scoring based on the standardized protocol and the medical records provided by the same guardian of the patients. The average value was then calculated.","through study completion, an average of 6 months",[14,17,20,23],{"measure":15,"description":16,"timeFrame":12},"YGTSS impairment subscale","Total score range: 0 - 50 points，A training evaluator and the guardian jointly completed",{"measure":18,"description":19,"timeFrame":12},"ocular and systemic Adverse Events (AEs)","ocular and systemic AEs will be summarized descriptively, including the number and proportion of participants with any adverse event or specific adverse-event subcategory, such as ocular versus non-ocular events, adverse events of special interest, and events leading to study discontinuation. If the severity grade changes, the event will be summarized according to the highest grade. Systemic and ocular adverse events will be summarized separately.",{"measure":21,"description":22,"timeFrame":12},"Self-Rating Depression Scale(SDS)","Number of items: 20,Data source: Filled out by the primary guardian",{"measure":24,"description":25,"timeFrame":12},"Gilles de la Tourette Syndrome-Quality of Life scale(GTS-QOL)","Number of items: 24, Data source: Filled out by the child and\u002For the primary caregiver",null,{"allocation":28,"interventionModel":29,"interventionModelDescription":26,"primaryPurpose":30,"observationalModel":26,"timePerspective":26,"maskingInfo":31},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":32,"maskingDescription":26,"whoMasked":33},"SINGLE",[34],"OUTCOMES_ASSESSOR","Children diagnosed clinically with PTD primarily characterized by abnormal blinking were recruited from multiple clinical centers and randomly assigned to two groups. The behavioral intervention group received \"attention-reduction intervention therapy,\" while the control group continued with their previous clinical treatment regimen. After the initial observation period, participants in both groups crossed over to receive the same attention-reduction intervention therapy for an additional treatment cycle. The study evaluated changes in Yale Global Tic Severity Scale Total Tic Severity Score (YGTSS-TTSS) scores at the end of each intervention cycle compared to baseline. This study is designed as a prospective, multicenter, randomized, controlled clinical trial to validate these findings.",[37,43],{"label":38,"type":39,"description":40,"interventionNames":41},"Behavioral intervention","EXPERIMENTAL","The behavioral intervention group received the attention reduction intervention therapy.",[42],"Behavioral: Reducing Attentional Interventions Therapy Treatment",{"label":44,"type":45,"description":46,"interventionNames":47},"Control group","SHAM_COMPARATOR","The control group did not receive the intervention therapy aimed at reducing attention, and subsequently was transferred to the attention reduction intervention therapy.",[48],"Other: Continue with the previous treatment plan",[50,54],{"type":51,"name":52,"description":52,"armGroupLabels":53,"otherNames":26},"BEHAVIORAL","Reducing Attentional Interventions Therapy Treatment",[38],{"type":6,"name":55,"description":55,"armGroupLabels":56,"otherNames":26},"Continue with the previous treatment plan",[44],[58],{"name":59,"role":60,"phone":61,"phoneExt":26,"email":62},"Dan Liang professor","CONTACT","0086-020-87330402","wuhaoeye@163.com",[64],{"facility":65,"status":26,"city":66,"state":26,"zip":26,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong 510080","Guangzhou","China","CN",{"type":70,"coordinates":71},"Point",[72,73],113.25,23.11667,{"lat":73,"lon":72},[76],{"name":77,"role":60,"phone":78,"phoneExt":26,"email":62},"dan,liang","0086-020-66607666",{"type":80,"investigatorFullName":81,"investigatorTitle":82,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Liang Dan","Professor","100657541","let-it-tic-in-childhood-provisional-eye-tic-100657541",false,"NCT07838428","Let It TiC in Childhood Provisional Eye Tic","A Multicenter, Randomized, Controlled Clinical Trial of Attention Reduction Intervention Therapy for Children With Transient Tic Disorder Primarily Characterized by Abnormal Blinking","LETITTIC","Inclusion Criteria:\n\n1. Age: Between 6 and 14 years old\n2. the diagnosis is PTD characterized by abnormal blinking as the main manifestation\n3. The legal guardian agrees and signs the informed consent form, and complies with the research protocol\n\nExclusion Criteria:\n\n1. Received any other behavioral intervention treatment or took related therapeutic drugs within the past 3 months.\n2. The current active allergic diseases\n3. There are any eye disorders that may cause confusion in the interpretation of the research results\n4. Having worn contact lenses within the past 3 months\n5. The researchers determined that the participants were not suitable to participate in this study due to other reasons","ALL","6 Years","14 Years",{"count":95,"type":96},134,"ESTIMATED","INTERVENTIONAL",[99],"NA","Clarify the effectiveness and safety of \"Reduced-Attention Intervention Therapy\" in treating children with Provisional tic disorder （PTD） who mainly exhibit abnormal blinking behavior",[102,103],"Tic Disorder","Provisional Tic Disorder",[105,106,107],"tic disorder","provisional tic disorder","behavioral intervention","NOT_YET_RECRUITING","2026-09-23",{"date":111,"type":112},"2026-09-24","ACTUAL",{"date":114,"type":96},"2026-10-01",{"date":116,"type":96},"2030-12-31",{"name":5,"class":6},1]